首項利用幹細胞治療亨廷頓舞蹈症的人體試驗展開
First human trial using stem cells for Huntington's disease begins
Updated at: June 26, 2026 at 09:15 AM
在2026年6月，醫療界迎來了一個重要的里程碑，啟動了REGEN4HD臨床試驗。
In June 2026, the medical community hit a major milestone with the launch of the REGEN4HD clinical trial.
這是全球首項針對亨丁頓舞蹈症，測試人類胚胎幹細胞衍生療法的研究。
This marks the world’s first human study testing an embryonic stem cell-derived therapy for Huntington’s disease.
亨丁頓舞蹈症是一種漸進式、遺傳性的神經退化性疾病，目前尚無治癒方法。
Huntington’s is a progressive, inherited neurodegenerative disorder that currently lacks a cure.
該研究由加州大學爾灣分校的Leslie M.
Led by Dr.
與旨在消除毒性蛋白的基因療法不同，這種再生療法涉及將細胞直接植入紋狀體——即大腦受該疾病影響最嚴重的區域。
Thompson at the University of California, Irvine, and supported by $12 million from the California Institute for Regenerative Medicine, the study aims to enroll 21 participants.
雖然此階段的主要目標是評估安全性和耐受性，但在臨床前的模型中，已展現出改善運動功能和恢復大腦信號傳導的樂觀結果。
Researchers hope these cells will replace lost neurons, repair damaged circuits, and provide protective support to existing nerve cells.
